Skip to content

Author

Stanley Wang

1 paper indexed here

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Open access Aug 2026

ALG-055009 in non-cirrhotic adults with metabolic dysfunction-associated steatohepatitis (HERALD): a randomised, double-blind, placebo-controlled, phase 2a trial.

BACKGROUND Thyroid hormone receptor β (THR-β) agonists reduce atherogenic lipids, hepatic fat, and improve histology in metabolic dysfunction-associated steatohepatitis (MASH). The phase 2a HERALD study evaluated the efficacy, safety, pharmacokinetics, and pharmacodynamics of the selective and potent THR-β agonist ALG-...

R. Loomba, Stanley Wang, Dimple Desai et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.